STOCK TITAN
  1. Home
  2. Sec-filings
  3. CAI
  4. [Form 4] Caris Life Sciences, Inc. Insider Trading Activity

Caris Life Sciences (CAI) director awarded 13,192 restricted stock unit shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PHILLIPS T DANNY reported acquisition or exercise transactions in this Form 4 filing.

Caris Life Sciences, Inc. director Phillips T. Danny received an equity award reported as 13,192 shares of Common Stock, reflected as a grant or award of restricted stock units. The award was at a stated price of $0.00 per share and increased his direct holdings to 133,060 shares. The restricted stock units vest in accordance with the applicable grant agreement.

Positive

  • None.

Negative

  • None.
Insider PHILLIPS T DANNY
Role Director
Type Security Shares Price Value
Grant/Award Common Stock F1 13,192 $0.00 $0.00
Holdings After Transaction: Common Stock — 133,060 shares (Direct)
Footnotes (1)
  1. F1. Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
Shares granted 13,192 shares Grant or award of restricted stock units reported as Common Stock
Stated grant price $0.00 per share Price field for the 13,192-share grant transaction
Holdings after transaction 133,060 shares Total direct Common Stock holdings following the award
10b5-1 plan status Unchecked Affirmative Rule 10b5-1 checkbox is false for this filing
restricted stock units financial
"Represents an award of restricted stock units which vest in accordance"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
grant, award, or other acquisition financial
"transaction code description is Grant, award, or other acquisition"
Rule 10b5-1 regulatory
"The filing’s Rule 10b5-1 checkbox is not checked"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

What insider transaction did Caris Life Sciences (CAI) report for Phillips T. Danny?
Caris Life Sciences reported that director Phillips T. Danny received a grant of 13,192 shares of Common Stock, described as an award of restricted stock units that vest under an applicable grant agreement, increasing his direct holdings to 133,060 shares.

How many Caris Life Sciences (CAI) shares does Phillips T. Danny hold after this Form 4?
Following the reported award, Phillips T. Danny directly holds 133,060 shares of Caris Life Sciences Common Stock. This reflects the addition of 13,192 shares from a grant of restricted stock units reported in the filing.

Was the Caris Life Sciences (CAI) insider award to Phillips T. Danny a market purchase or a grant?
The transaction is characterized as a grant or award acquisition, not a market purchase. The Form 4 notes an award of restricted stock units covering 13,192 shares at a stated price of $0.00 per share.

What type of equity did Phillips T. Danny receive from Caris Life Sciences (CAI)?
Phillips T. Danny received an award of restricted stock units tied to 13,192 shares of Common Stock. A footnote explains these restricted stock units vest in accordance with the applicable grant agreement.

Is the Caris Life Sciences (CAI) Form 4 transaction under a Rule 10b5-1 plan?
The filing’s Rule 10b5-1 checkbox is not checked, indicating the reported grant of 13,192 restricted stock unit–based shares was not affirmed as executed under a Rule 10b5-1 trading arrangement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
PHILLIPS T DANNY
(Last)(First)(Middle)
C/O CARIS LIFE SCIENCES, INC.
750 W. JOHN CARPENTER FREEWAY, SUITE 800
(Street)
IRVING TEXAS 75039
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/14/2026A13,192(1)A$0133,060D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
Remarks:
/s/ J. Russel Denton, Attorney-in-Fact08/14/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR